| 0.71 0.024 (3.44%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.13  |
1-year : | 1.34 |
| Resists | First : | 0.96 |
Second : | 1.14 |
| Pivot price | 0.78 |
|||
| Supports | First : | 0.67 |
Second : | 0.56 |
| MAs | MA(5) : | 0.73 |
MA(20) : | 0.81 |
| MA(100) : | 0.75 |
MA(250) : | 0.96  |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 7.6 |
D(3) : | 8.3 |
| RSI | RSI(14): 40.8 |
|||
| 52-week | High : | 2.34 | Low : | 0.53 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ TNYA ] has closed above bottom band by 11.7%. Bollinger Bands are 34.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.74 - 0.74 | 0.74 - 0.75 |
| Low: | 0.66 - 0.67 | 0.67 - 0.67 |
| Close: | 0.7 - 0.71 | 0.71 - 0.72 |
Tenaya Therapeutics, Inc. is a U.S.-based biotechnology firm focused on unearthing, advancing, and providing novel treatments for various cardiovascular diseases. The company harnesses advanced scientific platforms, including cellular regeneration, gene therapy, and precision medicine, to develop its therapeutic candidates. Among its primary therapeutic initiatives is TN-201, an adeno-associated virus (AAV)-based gene therapy engineered to tackle genetic hypertrophic cardiomyopathy (gHCM) arising from haploinsufficient mutations in the myosin binding protein C3 (MYBPC3) gene. A prominent compound in its pipeline is TN-301, a small molecule histone deacetylase 6 inhibitor (HDAC6i) slated for use in both heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). Tenaya is also progressing TN-401, another AAV-based gene therapy aimed at genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) resulting from specific plakophilin 2 (PKP2) gene anomalies. Further, an AAV gene therapy is under development that seeks to introduce the dwarf open reading frame (DWORF) gene into cardiac tissue to address dilated cardiomyopathy (DCM). Rounding out its innovative portfolio, the 'Reprogramming program' employs an AAV-driven approach for cardiac regeneration, striving to replenish heart cells lost in patients who experience heart failure subsequent to a prior myocardial infarction. Founded in 2016, Tenaya operates from its base in South San Francisco, California.
Fri, 05 Jun 2026
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow - Seeking Alpha
Thu, 04 Jun 2026
Morgan Stanley Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $2 - Moomoo
Thu, 04 Jun 2026
TNYA: Strong clinical progress and regulatory momentum for gene therapy and small molecule programs - TradingView
Wed, 03 Jun 2026
Gene therapy eases genetic heart condition in small Tenaya trial - Stock Titan
Tue, 02 Jun 2026
Tenaya Therapeutics to Report Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 Gene Therapy for HCM on June 3, 2026 - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 217 (M) |
| Held by Insiders | 2.1607e+008 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 26,080 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.832e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | 917.7 % |
| Return on Equity (ttm) | -38.5 % |
| Qtrly Rev. Growth | 225000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -26.57 |
| EBITDA (p.s.) | 81227.4 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -64 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 3.45 |
| Dividend | 0 |
| Forward Dividend | 2.875e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|